Abstract 1666P
Background
Substance use and mental health disorders significantly contribute to disparities in cancer care, particularly in urban underserved areas like the South Bronx, characterized by a substantial Latinx and Black population. This study aimed to evaluate the influence of substance use and mental illness on cancer care among newly diagnosed patients at the Lincoln Cancer Center.
Methods
A retrospective analysis was conducted on newly diagnosed cancer patients treated between January and August 2022. Various aspects of their cancer care journey were assessed, including delays in diagnosis, treatment selection, compliance with care, incidence of unscheduled emergency department/inpatient visits, rates of follow-up loss, and mortality. Substance use and mental health disorders were evaluated through electronic health record reviews and structured telephone interviews. Statistical analysis was performed using descriptive statistics and the independent samples T-test in SPSS. This study was approved by the Institutional Review Board at our hospital.
Results
The study included 208 patients, with 106 (51%) having substance use disorders, 41 (19.1%) with mental health disorders and 31 (14.9%) having both. Among patients with mental health disorders, 34% received medication and 12% had regular psychiatric care. Patients with mental health disorders but no substance use, tended to be diagnosed at later cancer stages (50% vs 41.3% at stage 4). Patient with either mental health disorders or substance use disorder has delayed cancer diagnosis from initial suspicion date (64.09 days vs 46.71 days, p = 0.154) and higher non-compliance to clinic visits (20.9% vs 14.0%, p=0.015) and higher ED visit (1.67 vs 1.27, p = 0.71), admission rate (0.98 vs 0.57, p=0.232) and mortality compared to those without, showing odds ratios of 1.203 [95% CI 0.50-2.89] although statistically insignificant due to the small sample size.
Conclusions
Patients with either mental health disorders or substance use disorder exhibited more diagnostic delays, higher non-compliance with their cancer care journey, increased ED/inpatient visits, and mortality rates. Addressing both physical and mental health is crucial for narrowing cancer disparities in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11